These findings may provide additional mechanism responsible for CBL anti-brain ischemic stroke and may also facilitate the discovery of a range of drugs that act on CREB/PGC-1α pathway to be further developed into therapeutic agents for ischemic stroke. This evidence concerns the gene CBL and ischemic stroke.